WCN26-6022 PARTIAL REMISSION, COMPLETE REMISSION, AND RELAPSE IN PATIENTS WITH PRIMARY MEMBRANOUS GLOMERULOPATHY AT 24 MONTHS OF TREATMENT WITH TWO RITUXIMAB REGIMENS

Read full text Summarise with VIRAT
Authors: A Castro Sánchez, Ricardo Ibarra Valenzuela, David Garcia Ramirez, Jose Fernando Real García, Julio David Rios Ramirez, A. L. Ramos, Luis Enrique Álvarez Rangel
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Primary membranous glomerulopathy (MN) is the leading cause of nephrotic syndrome (SN) in adults worldwide. As part of the treatment for MN, immunosuppression is indicated in patients with persistent NS, with rituximab emerging as a first-line therapy; however, different dosing regimens exist, and there is no consensus on which is most effective. The study aimed to compare the frequency of partial remission (PR), complete remission (CR), and relapses in patients with primary MN treated with two different rituximab regimens.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Vasculitis and related conditions Systemic Lupus Erythematosus Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106255–106255
Publication date
25 March 2026
Language
EN